Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LPCN with free AI briefings, catalyst countdowns, and dilution alerts.

LPCN · Lipocine Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$21.5M Cash on Hand
26.6mo Cash Runway
Follow LPCN by email Get an email when LPCN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LPCN, unsubscribe in one click. Privacy

📣 What LPCN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Brexanolone Depression, Postpartum Phase 3 · NCT07822321 Recruiting
Topical testosterone gel 1.62 % Male Hypogonadism Phase 3 · NCT02081300 Completed
d-Alpha-Tocopherol Nonalcoholic Steatohepatitis (NASH) Phase 2 · NCT04134091 Completed
LPCN 1148 Liver Cirrhosis Phase 2 · NCT04874350 Completed

Also used in these trials (approved or third-party drugs, not LPCN's own candidates): Testosterone Undecanoate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LPCN holds $21.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.4M/quarter from operations, an estimated runway of 26.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LPCN files for a raise →

👥 Who Owns LPCN

Insiders 4.1% Other 5%+ holders 7.3% Institutions (39 holders) 26.3% Public and other holders 62.3%
HolderTypeShares% of sharesAs of
Squadron Master Fund LP 5%+ holder (13G) 810,000 7.31% 2026-06-30
Ikarian Capital, LLC Institution (13G, 5%+) 508,556 4.59% 2026-03-31
Squadron Capital Management LLC Institution (13G, 5%+) 500,000 4.52% 2025-12-18
John W. Higuchi
Director · +35,754 options
Insider 241,365 2.18% 2026-09-29
Mahesh V. Patel
Chief Executive Officer, Director · +849,277 options
Insider 211,495 1.91% 2026-11-12
Krista Fogarty
Principal Accounting Officer · +59,606 options
Insider 1,727 0.02% 2024-03-08

Share count 11,073,439 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LPCN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LPCN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.